Form 4 for BSX Boston Scientific
Accepted 2024-01-02 00:00:00 ET · period of report 2023-12-29 · accession 0001225208-24-000107 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-01-02 | 2023-12-29+ | BSX | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | M - OptEx | $11.87 | +80.0K | 256.2K | +45% | +$949.1K |
| D | 2024-01-02 | 2024-01-01 | BSX | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | F - Tax | $57.81 | -10.9K | 185.1K | -6% | -$630.6K |
| D | 2024-01-02 | 2023-12-29 | BSX | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | S - Sale+OE | $57.50 | -81.9K | 174.2K | -32% | -$4.71M |
| DM | 2024-01-02 | 2023-12-29+ | BSX | Fitzgerald Joseph Michael | EVP, Group Pres, Cardiology | M - OptEx | $0.00 | -80.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-01 | M | A | 21,799 | $0.00 | 196,040 | D | — | — | (F2) On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. |
| 2 | Common | Common Stock | 2024-01-01 | F | D | 10,908 | $57.81 | 185,132 | D | — | — | |
| 3 | Common | Common Stock | 2023-12-29 | S | D | 81,940 | $57.50 | 174,241 | D | — | — | |
| 4 | Common | Common Stock | 2023-12-29 | M | A | 58,189 | $16.31 | 256,181 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2023-12-29 | M | D | 58,189 | $0.00 | 0 | D | $16.31 · — to 2025-02-23 | 58,189 Common Stock | (F5) Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. |
| 6 | Derivative | Performance Share Units | 2024-01-01 | M | D | 21,799 | $0.00 | 0 | D | — · 2023-12-31 to 2023-12-31 | 21,799 Common Stock | (F2) On February 17, 2021, the reporting person was awarded a target number of performance share units under the Company's 2021 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2021 adjusted free cash flow measured against its 2021 financial plan over the one-year performance period ending December 31, 2021 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 22, 2022, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon completion of the individual service period that ended on December 31, 2023. (F6) Each performance shares unit represents the Company's commitment to issue one share of Boston Scientific common stock. |